Cell line · CVCL_1490
Papers50
1 to 20 of 50
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Circulating Tumour Cell GALNT13 Expression Is Associated with Prognosis and Treatment Response in Non-Small Cell Lung Cancer. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MPND Loss Epigenetically Activates TGFβ/SMAD3 Signaling to Drive Tumor Progression and Metastasis in Non-Small Cell Lung Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| C1RL-AS1/microRNA-424-5p/adrenoceptor β2 axis: A novel regulatory mechanism in lung adenocarcinoma associated with immune infiltration and prognosis. | PLoS One | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability. | Cell Biosci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Oncogenic Mutant p53 Sensitizes Non-Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress-Dependent Induction of Mitochondrial Apoptosis. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks. | Immunity | 2024 | Its Methods give the RRID and name the line | PubMed | |
| FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Exosomes secreted by ST3GAL5high cancer cells promote peritoneal dissemination by establishing a premetastatic microenvironment. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. | Mol Cell | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Wnt signaling is boosted during intestinal regeneration by a CD44-positive feedback loop. | Cell Death Dis | 2022 | Its Methods give the RRID and name the line | PubMed | |
| A MET-PTPRK kinase-phosphatase rheostat controls ZNRF3 and Wnt signaling. | Elife | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells. | Oncotarget | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1490/papers